Asia Pacific Pharmaceutical Contract Manufacturing Market
完整報告名稱與涵蓋範圍
Asia Pacific Pharmaceutical Contract Manufacturing Market Competitive Landscape and Forecast till 2035
報告摘要
The Asia Pacific Pharmaceutical Contract Manufacturing Market Competitive Landscape and Forecast till 2035 report profiles leading Contract Development and Manufacturing Organizations (CDMOs) across the region. Asia Pacific features a highly competitive landscape comprising major global CDMO conglomerates, state-backed biopharmaceutical production hubs, and specialized active pharmaceutical ingredient (API) suppliers in China, India, South Korea, and Japan.
Key competitive strategies focus on expanding cGMP-certified biologic cleanrooms, offering end-to-end drug discovery-to-commercialization pipelines, and investing in continuous flow manufacturing. Strategic acquisitions of Western clinical trial facilities and long-term commercial supply agreements with global pharma giants serve as primary expansion vectors. Regional CDMO competitiveness will remain exceptionally high through 2035.
授權報價
| Single User Price | $750 USD |
| Multi User Licence (up to 10 users) | $1,000 USD |
| Enterprisewide Price (Global Site License) | $1,250 USD |
目錄 Table of Contents
TABLE OF CONTENT
1.1 Introduction 14
1.1 Market Share Analysis, 2025 14
1.2 competitor dashboard 15
1.3 Public Players Stock Summary 16
1.4 Comparative Analysis: Key Players Financial 16
1.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 17
1.5.1 FACILITY LAUNCH 17
1.5.2 INSPECTION 19
1.5.3 MANUFACTURING 19
1.5.4 MANUFACTURING AGREEMENT 19
1.5.5 COLLABORATION 21
1.5.6 INVESTMENT 21
1.5.7 SUPPLY CHAIN ADVANCEMENT 22
1.5.8 AGREEMENT 22
1.5.9 EXPANSION 22
1.5.10 ACQUISITION 23
1.5.11 WEBSITE LAUNCH 23
1.6 LIST OF KEY PLAYERS, BY COUNTRY 23
1.6.1 CHINA 23
1.6.2 INDIA 24
1.6.3 JAPAN 24
1.6.4 SOUTH KOREA 25
1.6.5 AUSTRALIA 25
1.6.6 REST OF ASIA PACIFIC 26
1.7 Actionable Intelligence Analysis for Major Aerosol and Nasal Spray Contract Manufacturers 27
1.7.1 MAYNE PHARMA - ADELAIDE, AUSTRALIA 27
1.7.1.1 COMPANY OVERVIEW 27
1.7.1.2 AEROSOL AND NASAL SPRAY PRODUCT/BRAND NAMES 27
1.7.1.3 NASAL SPRAY CAPABILITY 27
1.7.1.4 PACKAGING FORMATS 27
1.7.1.5 DELIVERY FORMAT 27
1.7.1.6 PRODUCTION TECHNOLOGIES 28
1.7.1.7 REGULATORY APPROVALS 28
1.7.1.8 MANUFACTURING CAPACITY & FACILITY FOOTPRINT 28
1.7.1.9 GEOGRAPHIC PRESENCE / APAC MANUFACTURING LOCATIONS 28
1.7.1.10 STERILE VS NON-STERILE MANUFACTURING CAPABILITIES 29
1.7.1.11 FILL-FINISH CAPABILITIES 29
1.7.1.12 END-USER FOCUS (OTC, RX) 29
1.7.1.13 ONGOING R&D 29
1.7.2 ASPEN PHARMACARE - MELBOURNE, AUSTRALIA 29
1.7.2.1 COMPANY OVERVIEW 29
1.7.2.2 AEROSOL AND NASAL SPRAY PRODUCT/BRAND NAMES 30
1.7.2.3 PACKAGING FORMATS 30
1.7.2.4 DELIVERY FORMAT 30
1.7.2.5 PRODUCTION TECHNOLOGIES 30
1.7.2.6 REGULATORY APPROVALS 31
1.7.2.7 MANUFACTURING CAPACITY & FACILITY FOOTPRINT 31
1.7.2.8 GEOGRAPHIC PRESENCE / APAC MANUFACTURING LOCATIONS 31
1.7.2.9 STERILE VS NON-STERILE MANUFACTURING CAPABILITIES 31
1.7.2.10 FILL-FINISH CAPABILITIES 31
1.7.2.11 END-USER FOCUS (OTC, RX) 31
1.7.2.12 ONGOING R&D 32
1.7.3 INTERPHIL LABORATORIES - PHILIPPINES 32
1.7.3.1 COMPANY OVERVIEW 32
1.7.3.2 AEROSOL AND NASAL SPRAY PRODUCT/BRAND NAMES 32
1.7.3.3 PACKAGING FORMATS 32
1.7.3.4 DELIVERY FORMAT 32
1.7.3.5 PRODUCTION TECHNOLOGIES 33
1.7.3.6 REGULATORY APPROVALS 33
1.7.3.7 MANUFACTURING CAPACITY & FACILITY FOOTPRINT 33
1.7.3.8 GEOGRAPHIC PRESENCE / APAC MANUFACTURING LOCATIONS 33
1.7.3.9 STERILE VS NON-STERILE MANUFACTURING CAPABILITIES 33
1.7.3.10 FILL-FINISH CAPABILITIES 34
1.7.3.11 END-USER FOCUS (OTC, RX) 34
1.7.3.12 ONGOING R&D 34
1.7.4 OLIC (THAILAND) LIMITED - THAILAND 34
1.7.4.1 COMPANY OVERVIEW 34
1.7.4.2 AEROSOL AND NASAL SPRAY PRODUCT/BRAND NAMES 35
1.7.4.3 PACKAGING FORMATS 35
1.7.4.5 PRODUCTION TECHNOLOGIES 35
1.7.4.6 REGULATORY APPROVALS 36
1.7.4.7 MANUFACTURING CAPACITY & FACILITY FOOTPRINT 36
1.7.4.8 GEOGRAPHIC PRESENCE / APAC MANUFACTURING LOCATIONS 36
1.7.4.9 STERILE VS NON-STERILE MANUFACTURING CAPABILITIES 36
1.7.4.10 FILL-FINISH CAPABILITIES 37
1.7.4.11 END-USER FOCUS (OTC, RX) 37
1.7.4.12 ONGOING R&D 37
1.7.5 AURIGENE PHARMACEUTICAL SERVICES LIMITED - INDIA 37
1.7.5.1 COMPANY OVERVIEW 37
1.7.5.2 AEROSOL AND NASAL SPRAY PRODUCT/BRAND NAMES 38
1.7.5.3 PACKAGING FORMATS 38
1.7.5.4 DELIVERY FORMAT 38
1.7.5.5 PRODUCTION TECHNOLOGIES 38
1.7.5.6 REGULATORY APPROVALS 39
1.7.5.7 MANUFACTURING CAPACITY & FACILITY FOOTPRINT 39
1.7.5.8 GEOGRAPHIC PRESENCE / APAC MANUFACTURING LOCATIONS 39
1.7.5.9 STERILE VS NON-STERILE MANUFACTURING CAPABILITIES 39
1.7.5.10 FILL-FINISH CAPABILITIES 40
1.7.5.11 ONGOING R&D 40
2 COMPANY PROFILES 41
2.1 WuXi AppTec 41
2.1.1 COMPANY OVERVIEW 41
2.1.2 FINANCIAL OVERVIEW 42
2.1.3 SERVICES OFFERED 43
2.1.4 KEY DEVELOPMENTS 44
2.1.5 SWOT ANALYSIS 45
2.1.6 KEY STRATEGIES 45
2.2 WuXi Biologics 46
2.2.1 COMPANY OVERVIEW 46
2.2.2 FINANCIAL OVERVIEW 47
2.2.3 SERVICES OFFERED 48
2.2.4 KEY DEVELOPMENTS 49
2.2.5 SWOT ANALYSIS 50
2.2.6 KEY STRATEGIES 50
2.3 Asymchem Inc 51
2.3.1 COMPANY OVERVIEW 51
2.3.2 FINANCIAL OVERVIEW 52
2.3.3 SERVICES OFFERED 53
2.3.4 KEY DEVELOPMENTS 55
2.3.5 SWOT ANALYSIS 56
2.3.6 KEY STRATEGIES 56
2.4 Pharmaron 57
2.4.1 COMPANY OVERVIEW 57
2.4.2 FINANCIAL OVERVIEW 58
2.4.3 SERVICES OFFERED 59
2.4.4 KEY DEVELOPMENTS 61
2.4.5 SWOT ANALYSIS 62
2.4.6 KEY STRATEGIES 62
2.5 Samsung Biologics 63
2.5.1 COMPANY OVERVIEW 63
2.5.2 FINANCIAL OVERVIEW 64
2.5.3 SERVICES OFFERED 65
2.5.4 KEY DEVELOPMENTS 68
2.5.5 SWOT ANALYSIS 69
2.5.6 KEY STRATEGIES 69
2.6 Piramal Pharma Solutions 71
2.6.1 COMPANY OVERVIEW 71
2.6.2 FINANCIAL OVERVIEW 72
2.6.3 SERVICES OFFERED 73
2.6.4 KEY DEVELOPMENTS 75
2.6.5 KEY STRATEGIES 76
2.7 SK pharmteco Inc 77
2.7.1 COMPANY OVERVIEW 77
2.7.2 FINANCIAL OVERVIEW 77
2.7.3 SERVICES OFFERED 78
2.7.4 KEY DEVELOPMENTS 79
2.7.5 KEY STRATEGIES 79
2.8 Divi's Laboratories 80
2.8.1 COMPANY OVERVIEW 80
2.8.2 FINANCIAL OVERVIEW 81
2.8.3 SERVICES OFFERED 82
2.8.4 KEY DEVELOPMENTS 83
2.8.5 KEY STRATEGIES 83
2.9 Gland Pharma 84
2.9.1 COMPANY OVERVIEW 84
2.9.2 FINANCIAL OVERVIEW 85
2.9.3 SERVICES OFFERED 86
2.9.4 KEY DEVELOPMENTS 86
2.9.5 KEY STRATEGIES 87
2.10 Syngene International 88
2.10.1 COMPANY OVERVIEW 88
2.10.2 FINANCIAL OVERVIEW 89
2.10.3 SERVICES OFFERED 90
2.10.4 KEY DEVELOPMENTS 90
2.10.5 KEY STRATEGIES 91
3 DATA CITATIONS 92
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 FACILITY LAUNCH 18
TABLE 2 INSPECTION 21
TABLE 3 MANUFACTURING 21
TABLE 4 MANUFACTURING AGREEMENT 21
TABLE 5 COLLABORATION 23
TABLE 6 INVESTMENT 23
TABLE 7 SUPPLY CHAIN ADVANCEMENT 24
TABLE 8 AGREEMENT 24
TABLE 9 EXPANSION 25
TABLE 10 ACQUISITION 26
TABLE 11 WEBSITE LAUNCH 26
TABLE 12 LIST OF KEY PLAYERS 26
TABLE 13 LIST OF KEY PLAYERS 27
TABLE 14 LIST OF KEY PLAYERS 27
TABLE 15 LIST OF KEY PLAYERS 29
TABLE 16 LIST OF KEY PLAYERS 29
TABLE 17 LIST OF KEY PLAYERS 30
TABLE 18 WUXI APPTEC: SERVICES OFFERED 54
TABLE 19 WUXI APPTEC: KEY DEVELOPMENTS 55
TABLE 20 WUXI BIOLOGICS: SERVICES OFFERED 61
TABLE 21 WUXI BIOLOGICS: KEY DEVELOPMENTS 62
TABLE 22 ASYMCHEM INC.: SERVICES OFFERED 66
TABLE 23 ASYMCHEM INC.: KEY DEVELOPMENTS 69
TABLE 24 PHARMARON: SERVICES OFFERED 75
TABLE 25 PHARMARON: KEY DEVELOPMENTS 78
TABLE 26 SAMSUNG BIOLOGICS: SERVICES OFFERED 82
TABLE 27 SAMSUNG BIOLOGICS: KEY DEVELOPMENTS 86
TABLE 28 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED 92
TABLE 29 PIRAMAL PHARMA SOLUTIONS: KEY DEVELOPMENTS 94
TABLE 30 SK PHARMTECO INC.: SERVICES OFFERED 98
TABLE 31 SK PHARMTECO INC.: KEY DEVELOPMENTS 100
TABLE 32 DIVI'S LABORATORIES: SERVICES OFFERED 105
TABLE 33 DIVI'S LABORATORIES: KEY DEVELOPMENTS 106
TABLE 34 GLAND PHARMA: SERVICES OFFERED 111
TABLE 35 SYNGENE INTERNATIONAL: SERVICES OFFERED 116
TABLE 36 SYNGENE INTERNATIONAL: KEY DEVELOPMENTS 116
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 15
FIGURE 2 COMPETITOR DASHBOARD: ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 16
FIGURE 3 WUXI APPTEC: FINANCIAL OVERVIEW SNAPSHOT 52
FIGURE 4 WUXI APPTEC: SWOT ANALYSIS 57
FIGURE 5 WUXI BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT 59
FIGURE 6 WUXI BIOLOGICS: SWOT ANALYSIS 63
FIGURE 7 ASYMCHEM INC.: FINANCIAL OVERVIEW SNAPSHOT 65
FIGURE 8 ASYMCHEM INC.: SWOT ANALYSIS 71
FIGURE 9 PHARMARON: FINANCIAL OVERVIEW SNAPSHOT 74
FIGURE 10 PHARMARON: SWOT ANALYSIS 79
FIGURE 11 SAMSUNG BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT 81
FIGURE 12 SAMSUNG BIOLOGICS: SWOT ANALYSIS 87
FIGURE 13 PIRAMAL PHARMA LIMITED: FINANCIAL OVERVIEW SNAPSHOT 90
FIGURE 14 DIVI'S LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 103
FIGURE 15 GLAND PHARMA: FINANCIAL OVERVIEW SNAPSHOT 110
FIGURE 16 SYNGENE INTERNATIONAL: FINANCIAL OVERVIEW SNAPSHOT 115
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們